Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Lung Cancer Research

Study Title:  International Early Lung Cancer Action Program (I-ELCAP)

Study Purpose: Determine the efficacy of low dose helical chest CT scan screening in reducing mortality of lung cancer.

Participants: Age 55-75 with a minimum 20 pack year smoking history (the equivalent of 1 pack/day for 20 years), without manifestations of lung cancer.

Principal Investigator: James C. Willey, MD

Study Coordinator: Stephanie Smiddy, RN. For more information please contact 419-383-6794


Study Title:  A151216:  Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).  (NCT02194738)

Study Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Principal Investigator: Roland Skeel, MD

Study Coordinator: Stephanie Smiddy, RN. For more information please contact 419-383-6794


Study Title:  A081105:  Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).  (NCT02193282)

Study Purpose: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Principal Investigator: Roland Skeel, MD

Study Coordinator: Stephanie Smiddy, RN. For more information please contact 419-383-6794


Study Title:  E4512:  A Phase 3 Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer:  Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.  (NCT02201992)

Study Purpose: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Principal Investigator: Roland Skeel, MD

Study Coordinator: Stephanie Smiddy, RN. For more information please contact 419-383-6794


Study Title:  Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase 3 Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers.  (NCT02595944)

Study Purpose:   This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Principal Investigator: Roland Skeel, MD

Study Coordinator: Stephanie Smiddy, RN. For more information please contact 419-383-6794

Last Updated: 7/21/16